Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz, R.P., Pettus, L.H., Xu, S., Henkle, B., Sherman, L., Plant, M., Miner, K., McBride, H., Wong, L.M., Saris, C.J., Lee, M.R., Chmait, S., Mohr, C., Hsieh, F., Tasker, A.S.(2009) Bioorg Med Chem Lett 19: 4724-4728
- PubMed: 19574047 
- DOI: 10.1016/j.bmcl.2009.06.058
- Primary Citation of Related Structures:  
3GFE - PubMed Abstract: 
A novel class of fused pyrazole-derived inhibitors of p38alpha mitogen-activated protein kinase (MAPK) is disclosed. These inhibitors were evaluated for their ability to inhibit the p38alpha enzyme, the secretion of TNFalpha in a LPS-challenged THP1 cell line and TNFalpha-induced production of IL-8 in 50% human whole blood ...